以岭药业2025年预盈12亿元—13亿元

Core Viewpoint - Yiling Pharmaceutical (002603) anticipates a net profit attributable to shareholders of 1.2 billion to 1.3 billion yuan for 2025, recovering from a loss of 725 million yuan in the previous year [1] Group 1: Financial Performance - The company expects a year-on-year recovery in operating revenue despite a complex market environment and competitive pressure [1] - Yiling Pharmaceutical has implemented comprehensive budget management and established a full-chain cost control system, leading to significant improvements in profit margins [1] Group 2: Business Segments - The main business of Yiling Pharmaceutical focuses on the research, production, and sales of patented innovative traditional Chinese medicine [1] - In the patented traditional Chinese medicine sector, the company has developed a unique competitive edge through the application of the theory of collateral diseases in clinical research, leading to advancements in new drug development [1] - The company currently holds 17 patented traditional Chinese medicines covering eight major clinical disease systems, with a leading position in the cardiovascular and respiratory disease medication fields [1] Group 3: Chemical and Health Industries - In the chemical medicine sector, Yiling Pharmaceutical has established R&D and production bases for solid oral dosage forms and non-cytotoxic oral anti-tumor solid dosage forms in Shijiazhuang and Beijing, with facilities certified by multiple countries [2] - The company has become one of the larger domestic enterprises for contract manufacturing and exporting formulations to Europe and the United States [2] - In the health industry segment, Yiling Pharmaceutical has developed a comprehensive health product R&D and management service system, integrating online and offline health services [2] - The company has launched a series of health products, including those aimed at cardiovascular health, anti-aging, fatigue relief, sleep improvement, and respiratory health [2]